Exclusive License of Angiochem’s Brain Cancer and Metastases, Geron (GERN)
December 8th, 2010
No comments
GERN obtained a worldwide, exclusive license to Angiochem‘s peptide technology, which is expected to help anticancer agents move across the blood-brain barrier (BBB). Read more…
Categories: Angiochem, NASDAQ: GERN, Worldwide exclusive license
